Introduction

Pregnancy is a complex physiological state in which the immune system must balance the defense against pathogens with the tolerance of the developing fetus, which is genetically distinct from the mother. e maternal immune system undergoes signi cant adaptations to ensure that the fetus is protected from infections while preventing immune rejection. However, excessive or dysregulated maternal immune activation, o en characterized by elevated levels of interleukins and other in ammatory cytokines, has been linked to a range of adverse pregnancy outcomes, including preterm birth, preeclampsia, fetal growth restriction, and neurodevelopmental disorders such as autism spectrum disorder. In ammatory cytokines, particularly interleukins (ILs), play a central role in regulating immune responses during pregnancy. e e ects of maternal immune activation on fetal development are profound, in uencing both short-term outcomes, such as preterm labor, and long-term outcomes, such as neurodevelopmental and metabolic disorders in o spring. is review explores the role of interleukins and in ammatory cytokines in maternal immune activation during pregnancy and examines their impact on fetal development [1].

Maternal Immune System Adaptations during Pregnancy

During pregnancy, the maternal immune system must maintain a delicate balance between immune tolerance and immune activation. e fetus is an allogra , containing paternal antigens that could potentially be recognized by the maternal immune system as foreign.

birth. Additionally, IL-1β influences the expression of adhesion molecules and cytokines within the placenta, contributing to placental dysfunction and inadequate fetal perfusion. Studies have shown that higher levels of IL-1β are associated with fetal growth restriction and adverse neurodevelopmental outcomes in the offspring, such as cognitive impairments and behavioral disorders [5].

IL-8 and Chemotaxis in Pregnancy

IL-8 is a chemokine that plays a critical role in the recruitment of immune cells to sites of infection or inflammation. It is produced by various cell types, including endothelial cells, macrophages, and neutrophils. During pregnancy, IL-8 is involved in the regulation of immune cell migration and the response to infection or inflammatory stimuli. Increased IL-8 levels in maternal circulation are often associated with intrauterine infection and preterm labor. The overproduction of IL-8 leads to the accumulation of neutrophils in the uterine tissues, which can promote inflammation, uterine contractions, and early labor. Elevated IL-8 levels have also been linked to adverse fetal outcomes, including preterm birth and fetal growth restriction. In addition, IL-8 may have a direct effect on fetal development, as it can influence placental function and the ability of the placenta to supply the fetus with adequate nutrients and oxygen.

IL-17 and Immune Dysregulation in Pregnancy

IL-17 is a pro-inflammatory cytokine produced primarily by T-helper 17 (17) cells, and it plays a significant role in the immune response to infections and in autoimmune diseases. Dysregulation of IL-17 production during pregnancy has been associated with preterm birth, fetal growth restriction, and placental dysfunction. IL-17 has been shown to increase the production of other inflammatory cytokines, including IL-6 and IL-1β, leading to a heightened inflammatory response in the maternal-fetal interface. Increased IL-17 levels in maternal serum have been linked to adverse pregnancy outcomes, such as preeclampsia, intrauterine inflammation, and spontaneous preterm deficit hyperactivity disorder (ADHD). Cytokines such as IL-6 and IL-1β can influence neuronal differentiation, synaptogenesis, and brain structure, potentially altering neural circuits and impairing cognitive and behavioral function. Furthermore, maternal inflammation can affect the development of the fetal immune system, increasing the risk of immune dysregulation and susceptibility to infections later in life. In addition to neurodevelopmental effects, maternal immune activation can influence the metabolic programming of the fetus. Altered cytokine levels during pregnancy have been linked to an increased risk of metabolic disorders, including obesity, diabetes, and cardiovascular diseases, in offspring. This phenomenon, known as fetal programming, suggests that inflammatory signals during pregnancy may permanently alter the development of key organs and systems in the fetus, leading to long-term health consequences.

Conclusion

The role of interleukins and inflammatory cytokines in maternal immune activation is critical for the regulation of both immune responses and fetal development during pregnancy. Dysregulation of these cytokines can lead to excessive inflammation, with profound effects on pregnancy outcomes and fetal health. Elevated levels of interleukins such as IL-6, IL-1β, IL-8, and IL-17 have been implicated in a range of pregnancy complications, including preterm birth, fetal growth restriction, and neurodevelopmental disorders in offspring. Understanding the molecular mechanisms underlying maternal immune activation and its impact on fetal development is crucial for identifying new therapeutic strategies to prevent or mitigate adverse pregnancy outcomes. Further research is needed to explore the complex interactions between maternal inflammation, cytokine signaling, and fetal development, with the goal of improving maternal and neonatal health outcomes.

References

1. Belzile M, Pouliot A, Cumyn A, C¹t® AM (2019) Renal physiology and þuid and electrolyte disorders in pregnancy. Best Pract Res Clin Obstet Gynaecol 57: 1-14.
2. Ali DS, Dandurand K, Khan AA (2021) Hypoparathyroidism in pregnancy and lactation: current approach to diagnosis and management. J Clin Med 10: 1378.
3. Almaghamsi A, Almalki MH, Buhary BM (2018) Hypocalcemia in pregnancy: a clinical review update. Oman Med J 33: 453-462.
4. Rey E, Jacob CE, Koolian M, Morin F (2016) Hypercalcemia in pregnancy – a multifaceted challenge: case reports and literature review. Clin Case Rep 4: 1001-1008.
5. Appelman Dijkstra NM, Ertl DA, Carola Zillikens M, Rjenmark L, Winter EM, et al. (2021) Hypercalcemia during pregnancy: management and outcomes for mother and child. Endocrine 71: 604-610.
6. Langer B, Grima M, Coquard C, Bader AM, Schlaeder G, et al. (1998) Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in preeclampsia. Obstet Gynecol 91: 196-202.